-
2023-505579-53-00
5
2022-10-25
Diffuse large B-cell lymphoma (DLBCL)
-
2023-506929-11-00
5
2022-10-17
Overweight and obesity
-
2023-508265-33-00
5
2022-10-13
Vasomotor symptoms caused by adjuvant endocrine therapy in women with,
-
2023-506927-27-00
5
2022-08-29
Children with short stature either born small for gestational age or w
-
2023-510145-25-00
5
2022-08-23
Meningococcal infection
-
2023-505255-51-00
5
2022-08-08
Herpes Zoster
-
2024-510800-35-00
5
2022-06-17
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2023-508897-27-00
5
2022-04-28
Multiple Myeloma
-
2023-506361-56-00
5
2022-04-01
Endometrial cancer
-
2023-503640-14-00
5
2022-02-17
Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
-
2023-503826-37-00
5
2022-02-11
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2023-504884-17-00
5
2022-02-04
Proteinuria
-
2023-509864-96-00
4
2021-12-07
Mantle Cell Lymphoma (MCL)
-
2023-509133-39-00
5
2021-11-29
Hormone receptor positive, HER2-negative advanced breast cancer
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2023-506256-25-00
5
2021-10-20
Active Psoriatic Arthritis
-
2022-502047-35-00
4
2021-10-07
Yellow fever
-
2023-508838-33-00
5
2021-10-06
Chronic Myeloid Leukemia
-
2023-509208-14-00
5
2021-09-28
MULTIPLE MYELOMA
-
2024-510809-28-00
5
2021-09-27
Metastatic Castration-sensitive Prostate Cancer
-
2024-512038-13-00
5
2021-09-16
Metastatic or unresectable locally advanced BRAF V600E/K mutation posi
-
2023-505850-16-00
5
2021-08-05
Multiple Myeloma
-
2023-506270-13-00
4
2021-07-27
Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)
-
2023-504684-16-00
5
2021-06-05
follicular lymphoma (FL) and marginal zone lymphoma (MZL)